RT info:eu-repo/semantics/article
T1 Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives
A1 Pinto Merino, Álvaro
A1 Labrador, Jorge
A1 Zubiaur, Pablo
A1 Alcaraz, Raquel
A1 Herrero, María José
A1 Montesinos, Pau
A1 Abad Santos, Francisco
A1 Saiz Rodríguez, Miriam
K1 Acute myeloid leukemia
K1 Pharmacogenetics
K1 Cytarabine
K1 Anthracyclines
K1 FLT3 inhibitors
K1 IDH inhibitors
K1 CD33 inhibitors
K1 Hypomethylating agents
K1 BCL2 inhibitors
K1 Leucemia mieloide aguda
K1 Acute myeloid leukemia
AB Acute myeloid leukemia (AML) is a heterogeneous disease characterized by remarkable toxicity and great variability in response to treatment. Plenteous pharmacogenetic studies have already been published for classical therapies, such as cytarabine or anthracyclines, but such studies remain scarce for newer drugs. There is evidence of the relevance of polymorphisms in response to treatment, although most studies have limitations in terms of cohort size or standardization of results. The different responses associated with genetic variability include both increased drug efficacy and toxicity and decreased response or resistance to treatment. A broad pharmacogenetic understanding may be useful in the design of dosing strategies and treatment guidelines. The aim of this study is to perform a review of the available publications and evidence related to the pharmacogenetics of AML, compiling those studies that may be useful in optimizing drug administration.
PB MDPI
YR 2022
FD 2022-03
LK https://hdl.handle.net/10259/12198
UL https://hdl.handle.net/10259/12198
LA eng
NO M.S.R. research was supported by Instituto de Salud Carlos III (ISCIII), Spanish Ministryof Science and Innovation, through the Sara Borrell Program (CD21/00022). P.Z. contract withCIBERehd is financed by the “Infraestructura de Medicina de Precisión asociada a la Ciencia yTecnología (IMPaCT, IMP/00009).
DS Repositorio Institucional de la Universidad de Burgos
RD 02-oct-2026